For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Phase 3 studies quality-of-life scores

Across 2 phase 3 studies, Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrated prolonged improvements in quality-of-life scores over baseline vs BRAF inhibitor monotherapy1,2

Quality of life with Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs. braf monotherapy 

Reprinted from Grob JJ, et al. Lancet Oncol. 2015;16(13):1389-1398, Copyright 2015, with permission from Elsevier.

Quality of life and overall global health for Tafinlar® (dabrafenib) + Mekinist® (trametinib)

  • Across the 2 phase 3 studies, Tafinlar + Mekinist demonstrated improvements in EORTC QLQ-C30 Global Health scores over baseline vs Tafinlar and vemurafenib monotherapy1,2

* Denotes statistical significance.
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; PD, progressive disease.

References: 1. Grob J-J, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389-1398. 2. Data on file.